`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDA 203858/S-009
`
`
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
`
`
`
`
`
`
` Aegerion Pharmaceuticals, Inc.
`
` Attention: Martha Carter
` Chief Regulatory Officer and Senior Vice President
`
` 101 Main Street, Suite 1850
`
` Cambridge, MA 02142
`
`
`
`
`Dear Ms. Carter:
`
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Application (sNDA) dated and received on
`
`
`
`
`May 28, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act
`
`(FDCA) for Juxtapid (lomitapide) Capsules, 5 mg, 10 mg, and 20 mg.
`
`
`
`
`
`
`
`This “Changes Being Effected” supplemental new drug application provides for revisions to the
`
`
`package insert (PI) to re-categorize the combination of tipranavir/ritonavir from the list of weak
`
`CYP3A4 inhibitors to the list of strong CYP3A4 inhibitors. As a result, revisions have been
`made to the DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and DRUG
`
`
`
`INTERACTIONS sections of the label. In addition, editorial revisions have been made to both
`
`the PI and the MedGuide.
`
`
`APPROVAL & LABELING
`
`We have completed our review of this supplemental application. It is approved, effective on the
`
`
`
`
`date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
`
`
`CONTENT OF LABELING
`
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`
`
`
`
`automated drug registration and listing system (eLIST), as described at
`
`
`
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`
`
`of labeling must be identical to the enclosed labeling (text for the package insert, Medication
`
`
`Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE)
`
`
`supplements, as well as annual reportable changes not included in the enclosed labeling.
`
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`
`
`
`“SPL Standard for Content of Labeling Technical Qs and As at
`
`
`
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf
`
`
`Reference ID: 3607102
`
`
`
`
`
`
`
`
`
` NDA 203858/S-009
`
` Page 2
`
`
` The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`Also within 14 days, amend all pending supplemental applications that includes labeling changes
`
`
`for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
`
`
`
`
`with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`changes approved in this supplemental application, as well as annual reportable changes and
`
`
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`
`
`
`
`
`
`should provide appropriate annotations, including supplement number(s) and annual report
`
`date(s).
`
`
`
`PROMOTIONAL MATERIALS
`
`You may request advisory comments on proposed introductory advertising and promotional
`
`
`
`
`
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`
`
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`(3) the package insert(s) to:
`
`
`
`Food and Drug Administration
`
`Center for Drug Evaluation and Research
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`You must submit final promotional materials and package insert(s), accompanied by a Form
`
`
`FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`
`
`
`
`
`FDA 2253 is available at
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf.
`Information and Instructions for completing the form can be found at
`
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For
`
`more information about submission of promotional materials to the Office of Prescription Drug
`
`
`
`Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
`
`
`All promotional materials that include representations about your drug product must be promptly
`
`
`revised to be consistent with the labeling changes approved in this supplement, including any
`
`
`
`
`new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials
`
`
`
`
`
`
`should include prominent disclosure of the important new safety information that appears in the
`
`
`revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent
`
`
`to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.
`
`
`
`
`
`
`
`REPORTING REQUIREMENTS
`
`
`
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`(21 CFR 314.80 and 314.81).
`
`
`Reference ID: 3607102
`
`
`
`
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Eric Colman, MD
`
`Deputy Director
`
`Division of Metabolism and Endocrinology Products
`
`
`Office of Drug Evaluation II
`
`Center for Drug Evaluation and Research
`
` NDA 203858/S-009
`
` Page 3
`
`
`
` If you have any questions, call Kati Johnson, Senior Regulatory Project Manager, at (301) 796
` 1234.
`
`
`
`
`
`
`
`ENCLOSURE:
`
`
`Content of Labeling
`
`Reference ID: 3607102
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`JAMES P SMITH
`08/08/2014
`on behalf of Eric Colman
`
`Reference ID: 3607102
`
`